Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | FAP | Q12884 | 3/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17722936 | 1.00 | KMT2A (0.37) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL19704786 | 1.00 | KMT2A (0.37) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL21018731 | 0.93 | FAP (0.36) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL21013510 | 0.93 | FAP (0.36) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL20887769 | 0.93 | FAP (0.36) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL25064904 | 0.92 | SMN1; SMN2 (0.38) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL20210383 | 0.92 | SMN1; SMN2 (0.38) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL21033557 | 0.92 | NR3C1 (0.36) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL16410974 | 0.91 | FAP (0.36) | KMT2AFAPNR3C1HDAC2CASP1 | |
| SCHEMBL29307620 | 0.91 | FAP (0.36) | KMT2AFAPNR3C1HDAC2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3804765-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3626273-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3212668-B1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3383909-B1 | ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3458102-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | KMT2A 1842/4885FAP 4569/4885NR3C1 1658/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | KMT2A 1842/4885FAP 4569/4885NR3C1 1658/4885 |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD47, CSGALNACT1, CSE1L | KMT2A 3228/4885FAP 4279/4885NR3C1 2778/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | KMT2A 46/4885FAP 3032/4885NR3C1 3679/4885 |
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | KMT2A 46/4885FAP 3032/4885NR3C1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.